Eisai Advances Alzheimer’s Care with LEQEMBI IQLIK Approval
TOKYO, Japan & CAMBRIDGE, Mass., July 13, 2026 Eisai Co., Ltd. and Biogen Inc. have achieved a major regulatory...
Early Alzheimer’s Disease
Advertisement
INmune Bio Reports Positive Phase 2 XPro Data
INmune Bio, BOCA RATON, Fla., July 9, 2026 INmune Bio Inc. announced positive new imaging findings from its Phase...
FDA Approves LEQEMBI IQLIK Subcutaneous Autoinjector for Maintenance Dosing in Early Alzheimer’s Disease
Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved LEQEMBI®...
Advertisement
